Zenodo (CERN European Organization for Nuclear Research)
October 19, 2026
Kimio Shiraishi
preprint
This preprint presents a focused critical narrative review of how safety findings for Cannabis and Psilocybe preparations are transferred across products, formulations, exposures, test systems, populations, and conditions of use. The central question is not whether safety evidence can ever be extrapolated, but when such extrapolation is justified and what information is needed to support it....
Journal of Happytalism and Fundamental Peace
October 18, 2026
Luis Miguel Gallardo
Background Psychedelic medicine is approaching regulatory approval, and suggestion alone can now occasion mystical-type experiences in the laboratory. Yet the field still names altered states after their triggers, and nobody can yet show whether the state itself, rather than its context, is what heals. Objective This review reads the evidence presented at the 2026 Annual Conference of the...
Alcoholism & Drug Abuse Weekly
October 16, 2026
Alison Knopf
A nationally representative cross‐sectional survey of U.S. adults found the among all psychedelics, ibogaine and 5‐MeO‐DMT (5‐methoxy‐N,N‐ dimethyltryptamine) resulted in the most frequent self‐reported adverse outcomes, according to a recent study. The study, “Adverse Health Outcomes of Psilocybin, LSD, MDMA, Ibogaine, and 5‐MeO‐DMT,” by Otto Simonsson, Ph.D., and colleagues, was published...
L'Encephale
October 16, 2026
Anne Buot, Jean-Del Burdairon, Luc Mallet et al.
The use of psychedelic substances such as LSD, psilocybin, and dimethyltryptamine is currently being re-evaluated for their therapeutic potential in psychiatry. While international clinical research had started in the 2010s, France only initiated its first psychedelic trials in 2024. This study aimed to explore the knowledge, perceptions, and attitudes of French mental health professionals...
The oncologist
October 15, 2026
Keenan Wills Davis, Michelle C. Bach, JoEllen Schimmels et al.
Psychedelic-assisted therapy (PAT) is increasingly discussed as a potential intervention for anxiety, depression, and existential distress among patients with advanced cancer. Yet the ethical challenges of PAT for patients approaching the end of life remain underdeveloped, particularly for oncologists who may be asked to counsel patients or consider referral to clinical trials. This article...
Western Journal of Emergency Medicine
October 14, 2026
Steven Chen, Rebecca Lipscomb, Rahul Mhaskar et al.
Introduction: Toxic mushroom exposures can occur through multiple mechanisms, including consumption as a delicacy, foraging, and use for psychoactive properties. Recent evidence suggests that psylocibin mushroom use is increasing in the United States. However, information on trends in mushroom poisonings in Florida is limited. This study aims to characterize trends in psychoactive and...
Trials
October 14, 2026
Luca Pani, Fabio Tascedda
Abstract: Background: The registry record of psychedelic and related rapid-acting compounds is large, heterogeneous and laborious to synthesize by hand. We tested whether a large language model (LLM) with live access to the ClinicalTrials.gov application programming interface (API) could produce a timely, structured and reproducible characterization of this landscape. Methods: Cross-sectional...
Lviv University Herald Series Psychological sciences
October 12, 2026
Ruslan Hanushchak, Игорь Прись
У статті здійснено ретроспективний огляд розвитку психоделічної терапії та проаналізовано сучасний стан досліджень її ефективності у лікуванні психічних розладів. Простежено еволюцію використання психоделічних речовин – від традиційних духовних і лікувальних практик корінних народів через ранні клінічні дослідження середини ХХ століття до сучасного етапу, так званого «психоделічного ренесансу»....
Nature Neuroscience
October 12, 2026
Drummond E-Wen Mcculloch, Kristian Larsen, Annette Johansen et al.
Lysergic acid diethylamide (LSD) is a potent psychedelic with increasing therapeutic interest, yet qualification of target engagement using in vivo neuroimaging has not yet been performed. Using simultaneous positron emission tomography-magnetic resonance imaging technology, we describe multiple brain actions of LSD in seven healthy volunteers blinded to LSD dose received. Here we show that LSD...
Psychiatry and Clinical Psychopharmacology
October 11, 2026
Kim Supit, Giordano N. Rossi, José Augusto S. Reis et al.
Background: Classic psychedelics, including LSD, psilocybin, and N,N-dimethyltryptamine (DMT)/ ayahuasca, have shown promise as rapid-acting treatments for psychiatric disorders. Because sleep plays a central role in emotional regulation and neuroplasticity, psychedelic-induced changes in sleep architecture are of interest.Methods: A systematic review was conducted following PRISMA guidelines....